These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9091649)

  • 1. Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor.
    Del Mastro L; Venturini M; Costantini M; Garrone O; Sertoli MR; Bertelli G; Machì AM; Rosso R
    J Natl Cancer Inst; 1997 Mar; 89(6):455-6. PubMed ID: 9091649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 3. Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
    Ardavanis A; Orphanos G; Skafida S; Basioukas S; Rigatos G
    Ann Oncol; 2008 Jul; 19(7):1360-1361. PubMed ID: 18534961
    [No Abstract]   [Full Text] [Related]  

  • 4. Patients' concerns about clinical trials in Japan.
    Aoki E
    Lancet; 1999 Mar; 353(9157):1019-20. PubMed ID: 10459946
    [No Abstract]   [Full Text] [Related]  

  • 5. Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
    Joaquim AI; Sagarra AJ; Ramos CD; Coudry R; Sagarra RA; Camargo EE
    Clin Nucl Med; 1997 Sep; 22(9):638-40. PubMed ID: 9298303
    [No Abstract]   [Full Text] [Related]  

  • 6. Recall phenomenon following epirubicin.
    Wilson J; Carder P; Gooi J; Nishikawa H
    Clin Oncol (R Coll Radiol); 1999; 11(6):424-5. PubMed ID: 10663338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
    Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
    Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
    du Bois A; Vach W; Holy R; Kriesinger-Schröder H
    Support Care Cancer; 1996 Sep; 4(5):384-9. PubMed ID: 8883233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sequencing of chemotherapy and radiotherapy following breast-preserving treatment of breast carcinoma].
    Sauer R; Martus P
    Strahlenther Onkol; 1996 Sep; 172(9):516-7. PubMed ID: 8928060
    [No Abstract]   [Full Text] [Related]  

  • 11. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
    Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
    Nolan L; Darby A; Boleti K; Simmonds P
    Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma.
    Beresford M; Lyburn I; Sanghera B; Makris A; Wong WL
    Breast J; 2007; 13(4):424-5. PubMed ID: 17593051
    [No Abstract]   [Full Text] [Related]  

  • 14. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
    Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
    Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
    Bonneterre J; Tubiana-Hulin M; Catimel G
    Oncology; 2004; 66(3):185-91. PubMed ID: 15218308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients.
    Jensen SB; Mouridsen HT; Bergmann OJ; Reibel J; Brünner N; Nauntofte B
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Aug; 106(2):217-26. PubMed ID: 18554960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 19. [The clinical and pharmacokinetic results of intrapleural epirubicin application].
    Schilcher RB; Rahn AN; Scheulen ME
    Strahlenther Onkol; 1997 Apr; 173(4):236-7. PubMed ID: 9148436
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.